Quick Answer
Kalaris Therapeutics, Inc. reported Earnings Per Share Diluted of $2.85 (loss) per share for the year ending 2025.
- Kalaris Therapeutics, Inc. showed an increase of +94.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Kalaris Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 4.0%.
- Historical annual values: Fiscal year 2025: $2.85 (loss) per share | Fiscal year 2024: $51.77 (loss) per share | Fiscal year 2023: $42.09 (loss) per share | Fiscal year 2022: $2.20 (loss) per share | Fiscal year 2021: $2.74 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: